Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Access Pharmaceuticals, a biopharmaceutical company, has closed the acquisition of MacroChem, a specialty pharmaceutical company, through the issuance of 2.5 million shares of Access Pharmaceuticals's common stock, as previously announced.
Subscribe to our email newsletter
Access gains the rights to MacroChem’s product portfolio which includes two clinical stage oncology products, 4-thio Ara-C (thiarabine), which is a next generation nucleoside analogue licensed from Southern Research Institute and sodium phenylbutyrate, which is licensed from the National Institutes of Health.
MacroChem’s portfolio of late stage clinical drug candidates includes Pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection that has already completed two Phase III clinical trials; EcoNail, a novel topical treatment for onychomycosis that completed a Phase II clinical trial; and two proprietary dermatology drug platforms, Sepa and MacroDerm.
Jeffrey Davis, president and CEO of Access, said: “The acquisition of MacroChem brings additional late-stage clinical drug candidates into the Access pipeline. We are currently active in partnering and out-licensing discussions, and MacroChem’s assets will be added to that partnering effort.
“The oncology assets are highly synergistic with the oncology development efforts ongoing at Access and we look forward to the opportunity to move them along in the clinic.”